Mendes Diana, Bains Iren, Vanni Tazio, Jit Mark
Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury, London, WC1E 7HT, UK.
Modelling and Economics Unit, Public Health England, 61 Colindale Avenue, London, NW9 5EQ, UK.
BMC Cancer. 2015 May 1;15:334. doi: 10.1186/s12885-015-1332-8.
Optimising population-based cervical screening policies is becoming more complex due to the expanding range of screening technologies available and the interplay with vaccine-induced changes in epidemiology. Mathematical models are increasingly being applied to assess the impact of cervical cancer screening strategies.
We systematically reviewed MEDLINE®, Embase, Web of Science®, EconLit, Health Economic Evaluation Database, and The Cochrane Library databases in order to identify the mathematical models of human papillomavirus (HPV) infection and cervical cancer progression used to assess the effectiveness and/or cost-effectiveness of cervical cancer screening strategies. Key model features and conclusions relevant to decision-making were extracted.
We found 153 articles meeting our eligibility criteria published up to May 2013. Most studies (72/153) evaluated the introduction of a new screening technology, with particular focus on the comparison of HPV DNA testing and cytology (n = 58). Twenty-eight in forty of these analyses supported HPV DNA primary screening implementation. A few studies analysed more recent technologies - rapid HPV DNA testing (n = 3), HPV DNA self-sampling (n = 4), and genotyping (n = 1) - and were also supportive of their introduction. However, no study was found on emerging molecular markers and their potential utility in future screening programmes. Most evaluations (113/153) were based on models simulating aggregate groups of women at risk of cervical cancer over time without accounting for HPV infection transmission. Calibration to country-specific outcome data is becoming more common, but has not yet become standard practice.
Models of cervical screening are increasingly used, and allow extrapolation of trial data to project the population-level health and economic impact of different screening policy. However, post-vaccination analyses have rarely incorporated transmission dynamics. Model calibration to country-specific data is increasingly common in recent studies.
由于可用筛查技术范围不断扩大以及与疫苗引起的流行病学变化相互作用,优化基于人群的宫颈癌筛查政策正变得越来越复杂。数学模型越来越多地被用于评估宫颈癌筛查策略的影响。
我们系统检索了MEDLINE®、Embase、Web of Science®、EconLit、卫生经济评估数据库和Cochrane图书馆数据库,以识别用于评估宫颈癌筛查策略有效性和/或成本效益的人乳头瘤病毒(HPV)感染及宫颈癌进展的数学模型。提取了与决策相关的关键模型特征和结论。
我们发现截至2013年5月有153篇文章符合我们的纳入标准。大多数研究(72/153)评估了新筛查技术的引入,尤其侧重于HPV DNA检测与细胞学检查的比较(n = 58)。其中40项分析中有28项支持实施HPV DNA初筛。少数研究分析了更新的技术——快速HPV DNA检测(n = 3)、HPV DNA自我采样(n = 4)和基因分型(n = 1)——并且也支持引入这些技术。然而,未发现关于新兴分子标志物及其在未来筛查项目中潜在用途的研究。大多数评估(113/153)基于模拟宫颈癌高危女性总体人群随时间变化的模型,未考虑HPV感染传播情况。根据特定国家结局数据进行校准正变得越来越普遍,但尚未成为标准做法。
宫颈癌筛查模型的使用越来越多,并且能够外推试验数据以预测不同筛查政策对人群健康和经济的影响。然而,疫苗接种后的分析很少纳入传播动态。在最近的研究中,根据特定国家数据进行模型校准越来越普遍。